Rua Life Sciences PLC
LSE:RUA
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| UK |
|
Rua Life Sciences PLC
LSE:RUA
|
9m GBP |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
60B USD |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
8.9T JPY |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
29.6B CHF |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
109.6B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.5B USD |
Loading...
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.6B GBP |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
42.8B CNY |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
6B USD |
Loading...
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
3.9B CHF |
Loading...
|
|
| US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
4.8B USD |
Loading...
|
Market Distribution
| Min | -188 120% |
| 30th Percentile | 0% |
| Median | 0% |
| 70th Percentile | 0.1% |
| Max | 10 443.9% |
Other Profitability Ratios
Rua Life Sciences PLC
Glance View
RUA Life Sciences Plc is a holding company, which engages in the commercialization of biomedical polymer technology, components, and medical devices. The company is headquartered in Ayrshire, Ayrshire and currently employs 32 full-time employees. The firm is a manufacturer of medical devices and licensor of its IP and know-how together with developing medical devices utilizing its polymer IP. The firm operates through four businesses. Its RUA Medical business provides sub-contract manufacturing, assembly, packing and services to the medical device sector from its Class seven and eight cleanroom suites. Its RUA Biomaterials is the depository of the IP and licensing rights to a range of biostable, implantable polymers, including Elast-EonTM and ECSilTM. Its RUA Vascular business is the legal manufacturer and IP holder of the Company’s cardiovascular and soft tissue patches and bore vascular grafts. Its RUA Structural Heart business holds the intellectual property relating to the Company’s synthetic heart valve technology.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Rua Life Sciences PLC is 0%, which is above its 3-year median of -50.2%.
Over the last 3 years, Rua Life Sciences PLC’s Net Margin has increased from -127% to 0%. During this period, it reached a low of -127% on Mar 3, 2022 and a high of 6.9% on Sep 30, 2024.
